The FASN inhibitor, TVB3664, Ameliorates NASH in a Murine Model
AASLD
PUBLICATIONS
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Progressive Reductions in Hepatic DNL with Increasing Doses of TVB-2640, a First-in-Class Pharmacologic Inhibitor of FASN
Keystone Symposium on Organ Crosstalk in Obesity and NAFLD
Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH
EASL International Liver Congress
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target
Pharmacology and Therapeutics
